Posted this with a link to an article explaining it on Facebook, this is my Facebook post: "This is what is kind of "ugly" on the Wall Street "Cancer Wars." You all know I am invested in Geron which has the only drug that has ever been shown to cause remission in the type of blood cancer it is battling. Meanwhile, Incyte Corporation has been around for a while, they're already got an approved drug that improves the cancer symptoms in people who have the cancer, but can't do squat to cure it. In an ideal world, this would be a double victory, one research effort is finding a cure, the other is helping the symptoms. But under capitalism, this all just sucks. Everyone is framing this up as Geron vs. Incyte and it's all about, "Who will win?" "Will it be Geron's drug that appears to be delivering a cure to some people, or will it be Incyte that delivers relief?" I honestly HATE this, but this is the big debate we're in. I honestly say, that maybe there's a bit of mutual room here because although Geron is pretty impressive with Imetelsat, we're not close to 100% cures and while Incyte has impressive symptom relief, they've never cured a person. I just don't like how it's a battle between the two companies on Wall Street rather than a story on how both companies have both made breakthroughs and people suffering from the disease are going to win on two fronts..."
There are advantages to collaboration. Let us consider Gilead Sciences, or Celgene, or Amgen and not dwell on Incyte. With the right partnership or buy out, which I would support as a shareholder, imetelstat could be a winner in a win-win scenario.
Throw in the market share consideration that pharmas often follow instead of efficacy, and you have something that the FDA has to alter through regulations. Even packaging can add to costs, and that is done just for marketing purposes without considering the addition to health care costs. This market share problem, plus the costs of clinical trials are the likely reasons that Geron has abandoned studies of solid tumors at least for now.
The current issue with GERN and Imetelstat is the publication of their Path Forward.
There are plenty of questions and few answers right now.
There is also lots of additional human testing before Imetelstat is approved to market.
Once Geron can figure out the common denominator that made the 41% receptive to treatment geron will be over twice as attractive. That day will come beleive me. Hopefully sooner than later.
Sentiment: Strong Buy
Mayo (also Hopkins, Cleveland, etc.) is an independent clinic, and is in a position to combine drugs, if that seems promising. Cancer is not one disease, but many that are capable of mutating. This is early days, and all combinations (symptoms, remissions, cures), and relations are possible. I believe that capitalism makes "coming together" more likely.